Curaleaf Laboratories, part of Curaleaf International, has launched the Curaleaf Que Medical Inhalation Device (QMID) in the UK, described as the first CE-certified liquid inhaler for cannabis-based medicines.
The device, available on prescription, has been approved as an EU Class IIa medical device under the EU Medical Device Regulation and is designed to deliver controlled doses of liquid cannabis extracts. Curaleaf said it provides a more precise and discreet alternative to consumer-grade vaporisers.
Jonathan Hodgson, UK managing director at Curaleaf International, said: ‘For the first time, inhaled liquid cannabis can be administered with controlled precision through a registered handheld device — giving prescribers and patients new confidence in treatment delivery.’
Developed with Jupiter Research, a subsidiary of TILT Holdings, the inhaler is rechargeable and compatible with Curaleaf’s EU-GMP liquid extract cartridges. The company said cartridges are available in 0.5mL and 1.0mL formats, with the larger size delivering up to 240 inhalations.
The launch comes as demand for cannabis-based products for medicinal use continues to grow. Since the UK legalised specialist prescribing in 2018, more than 60,000 patients have accessed cannabis-based medicines. Curaleaf said it is also working with regulators in Germany, Poland and Australia to register the device in other markets.
Juan Martinez, international chief executive of Curaleaf, said: ‘The launch of this certified Curaleaf device reflects the next phase of innovation and positions Curaleaf at the forefront of a differentiated, pharma-grade delivery platform that addresses growing global demand for precision cannabis therapies.’
©2026 All rights reserved LaingBuisson
 in the UK, described as the first CE-certified liquid inhaler for cannabis-based medicines.){kind=link}